Waters Introduces Next-Generation Alliance iS HPLC System Aimed at Reducing Up to 40% of Common Lab Errors
20.3.2023 15:00:00 EET | Business Wire | Press release
PITTCON 2023 – Waters Corporation (NYSE:WAT) today introduced Alliance iS, the next-generation intelligent HPLC System, designed to reduce compliance risk by adding new levels of proactive error detection, troubleshooting and ease-of-use. When combined with Waters’ compliance-ready Empower Chromatography Software and eConnect™ HPLC Columns, the Alliance iS High Performance Liquid Chromatography (HPLC) System streamlines the task of making accurate and precise measurements by detecting and eliminating common errors by up to 40%.i In doing so, the Alliance iS HPLC System helps QC laboratories consistently meet quality, safety, compliance, and on-time product delivery goals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230320005167/en/
The new Waters Alliance iS HPLC System is an intuitively simple, rugged, and reliable high performance liquid chromatograph designed specifically for the pharmaceutical quality control (QC) laboratory. The instrument makes QC laboratories more efficient by reducing common errors that cause up to 40% of failed sample sets and subsequent out-of-specification results, re-tests and investigations. (Photo: Business Wire)
“Today’s QC laboratories are very different than they were 50 years ago when Waters introduced its first commercial HPLC system helping ensure the tens of thousands of prescription drugs on the market are pure, safe, and will work as expected,” said Udit Batra, President & CEO, Waters Corporation. “Our conversations with hundreds of QC managers and bench analysts have yielded a deeper understanding of what they need today from a state-of-the-art HPLC system to help them perform at their best. The Waters Alliance iS HPLC System is ideally suited to address issues such as staff training, error-reduction, risk management, and compliance, helping bring significant productivity and quality improvements to high-volume QC laboratories.”
Based on broad and in-depth customer insights, the Alliance iS HPLC System is thoughtfully designed for the unique needs of the QC laboratory, bringing intuitive simplicity to routine measurements. With visual prompts and alerts delivered via an intuitive touchscreen interface, the system notifies the operator if an improper method is chosen for an application, when a sample vial is missing, when it’s time to refill a solvent bottle, or if it’s time for system maintenance. These are common conditions that when caught early enough, can eliminate system errors that would otherwise degrade the ability of scientists to get needed drugs to patients and ultimately cost a laboratory time and money.
The system also integrates with the cloud-native waters_connect™ System Monitoring Software enabling real-time monitoring of the Alliance iS HPLC System and any other chromatography instruments controlled by Empower Software. Laboratory managers can view the live status of their HPLC instrument fleet from anywhere and at any time to further improve equipment utilization and overall productivity.ii
Waters Alliance iS HPLC System feature highlights include:
- The very latest compliance-ready, industry-standard Empower Chromatography Software with full audit tracking capabilities.
- Advanced instrument touchscreen for guided system operation and maintenance.
- eConnect Column Tag Technology to link column information including injection counts via near-field communication (NFC) technology.
- Automated system diagnostic pre-checks to help meet error reduction key performance indicators (KPIs).
- Tool-free fittings to prevent leaks and provide better chromatography.
The Waters Alliance iS HPLC System will be available starting in May 2023.
Additional Resources
- Learn more about Waters Alliance iS HPLC System product features and benefits
- Download the Alliance iS HPLC System brochure
- Read the blog post Waters Pushes the Boundaries with Intuitive Simplicity
- Visit the Waters online press kit for Alliance iS and PittCon ’23 news
- Follow and connect with Waters via LinkedIn, Twitter, and Facebook
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for more than 60 years. With more than 8,200 employees worldwide, Waters operates directly in more than 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.
Waters, Alliance, eConnect, waters_connect, and Empower are trademarks of Waters Corporation.
i *Estimate based on Waters' market research in 2022 after surveying 56 global pharmaceutical company QC labs.
ii The waters_connect System Monitoring application is only available in Europe and North America at this time.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230320005167/en/
Contact information
Brian J. Murphy
PR Manager, Corporate Communications
Waters Corporation
brian_j_murphy@waters.com
+1 508-482-2614
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom